Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
CNY 19.91
(-0.75%)
CNY 19.91
(-0.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 391.09 Million CNY | -18.25% |
| 2022 | 425.27 Million CNY | 12.38% |
| 2021 | 422.41 Million CNY | 36.65% |
| 2020 | 339.17 Million CNY | -6.74% |
| 2019 | 328.66 Million CNY | 25.81% |
| 2018 | 260.83 Million CNY | 21.64% |
| 2017 | 225.49 Million CNY | 32.94% |
| 2016 | 155.69 Million CNY | 20.76% |
| 2015 | 132.84 Million CNY | 18.91% |
| 2014 | 110.71 Million CNY | 28.51% |
| 2013 | 86.73 Million CNY | 29.17% |
| 2012 | 73.18 Million CNY | 39.99% |
| 2011 | 53.33 Million CNY | 106.73% |
| 2010 | 27.31 Million CNY | 174.64% |
| 2009 | 9.11 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 83.45 Million CNY | -4.86% |
| 2024 Q3 | 143.3 Million CNY | 48.52% |
| 2024 Q1 | 89.31 Million CNY | 78.06% |
| 2023 Q4 | 40.12 Million CNY | -72.23% |
| 2023 FY | - CNY | -18.25% |
| 2023 Q1 | 75.88 Million CNY | 18.79% |
| 2023 Q2 | 86.98 Million CNY | 14.63% |
| 2023 Q3 | 144.5 Million CNY | 66.13% |
| 2022 FY | - CNY | 12.38% |
| 2022 Q4 | 63.87 Million CNY | -62.83% |
| 2022 Q1 | 105.16 Million CNY | 43.28% |
| 2022 Q2 | 105.14 Million CNY | -0.02% |
| 2022 Q3 | 171.85 Million CNY | 63.44% |
| 2021 Q3 | 152.14 Million CNY | 77.15% |
| 2021 FY | - CNY | 36.65% |
| 2021 Q1 | 83.62 Million CNY | 59.64% |
| 2021 Q2 | 85.88 Million CNY | 2.7% |
| 2021 Q4 | 73.39 Million CNY | -51.76% |
| 2020 Q1 | 39.99 Million CNY | -14.1% |
| 2020 FY | - CNY | -6.74% |
| 2020 Q4 | 52.38 Million CNY | -59.74% |
| 2020 Q3 | 130.12 Million CNY | 86.16% |
| 2020 Q2 | 69.9 Million CNY | 74.78% |
| 2019 FY | - CNY | 25.81% |
| 2019 Q4 | 46.56 Million CNY | -65.15% |
| 2019 Q3 | 133.6 Million CNY | 98.65% |
| 2019 Q2 | 67.25 Million CNY | -6.42% |
| 2019 Q1 | 71.87 Million CNY | 79.71% |
| 2018 Q1 | 58.37 Million CNY | 51.25% |
| 2018 Q4 | 39.99 Million CNY | -59.59% |
| 2018 FY | - CNY | 21.64% |
| 2018 Q3 | 98.96 Million CNY | 72.27% |
| 2018 Q2 | 57.44 Million CNY | -1.6% |
| 2017 Q1 | 44.57 Million CNY | 60.41% |
| 2017 Q2 | 43.08 Million CNY | -3.34% |
| 2017 Q3 | 82.97 Million CNY | 92.59% |
| 2017 Q4 | 38.59 Million CNY | -53.49% |
| 2017 FY | - CNY | 32.94% |
| 2016 FY | - CNY | 20.76% |
| 2016 Q1 | 33.49 Million CNY | 27.16% |
| 2016 Q2 | 27.43 Million CNY | -18.08% |
| 2016 Q3 | 67.61 Million CNY | 146.4% |
| 2016 Q4 | 27.78 Million CNY | -58.9% |
| 2015 FY | - CNY | 18.91% |
| 2015 Q4 | 26.34 Million CNY | -44.97% |
| 2015 Q3 | 47.86 Million CNY | 73.22% |
| 2015 Q2 | 27.63 Million CNY | -1.97% |
| 2015 Q1 | 28.18 Million CNY | 17.51% |
| 2014 Q1 | 16.48 Million CNY | 9.78% |
| 2014 Q4 | 23.98 Million CNY | -44.65% |
| 2014 Q3 | 43.33 Million CNY | 72.73% |
| 2014 Q2 | 25.09 Million CNY | 52.18% |
| 2014 FY | - CNY | 28.51% |
| 2013 Q1 | 18.14 Million CNY | 140.41% |
| 2013 FY | - CNY | 29.17% |
| 2013 Q4 | 15.01 Million CNY | -54.26% |
| 2013 Q3 | 32.83 Million CNY | 85.58% |
| 2013 Q2 | 17.69 Million CNY | -2.49% |
| 2012 FY | - CNY | 39.99% |
| 2012 Q4 | -44.9 Million CNY | -184.68% |
| 2012 Q3 | 53.03 Million CNY | 0.0% |
| 2011 FY | - CNY | 106.73% |
| 2010 FY | - CNY | 174.64% |
| 2009 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 1.14 Billion CNY | 65.742% |
| Zhejiang Zhenyuan Share Co., Ltd. | 220.46 Million CNY | -77.398% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -83.34 Million CNY | 569.26% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -2.67 Million CNY | 14738.241% |
| Yifan Pharmaceutical Co., Ltd. | -483.52 Million CNY | 180.884% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 66.15 Million CNY | -491.217% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 4.85 Billion CNY | 91.949% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 116.49 Million CNY | -235.72% |
| Boai NKY Medical Holdings Ltd. | 665.28 Million CNY | 41.214% |